传统,替代和新兴的治疗方法用于焦点细分型淋巴结核硬化
Silvia Di Carlo1, Elisa Longhitano1, Claudia Spinella1
1Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, A.O.U. "G.Martino", University of Messina, Messina, Italy.
Expert opinion on pharmacotherapy
|January 2, 2025
概括
细分焦点淋巴结核硬化症 (FSGS) 治疗是复杂的,因为它的各种原因. 策略包括对初级FSGS进行免疫抑制,准潜在因素,并提供支持性护理,以管理蛋白尿和缓慢损伤.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
- 病理学 病理学 病理学
背景情况:
- 细分焦点淋巴结核硬化 (FSGS) 是一种病,其特征是受细胞损伤.
- FSGS有不同的病因,包括原发性,遗传性,病毒性,有毒性和适应性原因,使治疗复杂化.
- 了解FSGS异质性对于有效的治疗策略至关重要.
研究的目的:
- 审查目前和新兴的FSGS治疗方法.
- 根据KDIGO 2021指南和文献审查提供指导.
- 突出FSGS管理中的挑战和个性化方法.
主要方法:
- 在PubMed上进行文献搜索.
- 对FSGS处理的KDIGO 2021指南的审查.
- 综合传统和新的治疗策略.
主要成果:
- 免疫抑制对初级FSGS有效,但对其他形式可能有害.
- 针对潜在原因,脏血液动力学和纤维化是关键策略.
- 控制血压和限制盐分是重要的支持措施.
结论:
- 个性化治疗FSGS需要基于临床,遗传和组织学数据的患者分层.
- 新兴疗法旨在解决FSGS中的特定病理途径.
- 优化FSGS治疗需要考虑疾病异质性的量身定制方法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
133
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
133
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135
Open Angle Glaucoma: Treatment
391
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
391
Antihypertensive Drugs: Direct Renin Inhibitors
484
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
484


